StockData

Exozymes Inc. (EXOZ) company profile

EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$3.31−0.68 (-17.04%)

Close on Nov 17, 2026Market cap $30.72MP/E –Yield –

About Exozymes

Biological Products, (No Diagnostic Substances), SIC 2836

eXoZymes Inc. is a biomanufacturing platform company that develops cell-free biosolutions to produce chemicals and small-molecule active ingredients. The company leverages artificial intelligence and bioengineering to design stabilized enzyme catalysts, termed exozymes, which operate outside living cells within bioreactors to convert feedstocks into valuable compounds. Its primary commercial focus targets low-volume, high-value natural products and derivatives for the nutraceutical sector that possess potential application as active pharmaceutical ingredients. Additionally, the company develops specialized programs including an exozyme pathway for isobutanol production to support sustainable aviation fuels and industrial chemical applications. Its customers and collaborative partners comprise commercial entities in the nutraceutical and pharmaceutical industries, as well as government agencies supporting applied research.

The company operates its research and development activities from a state-of-the-art laboratory facility. Headquartered in Monrovia, California, eXoZymes conducts its administrative and development functions within the United States.

Summary of the business section of Exozymes's latest annual report, written by StockData.

Company profile

Company

Legal name
Exozymes Inc.
Headquarters
Monrovia, CA
Address
750 Royal Oaks Dr 91016
Phone
(626) 415-1488
Employees
32, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
RBSM LLP, Las Vegas, Nevada

Stock & identifiers

Ticker
EXOZ
Former tickers
IZTC until Feb 11, 2025
Exchange
Nasdaq
IPO date
Nov 12, 2024
Shares outstanding
9M, Aug 13, 2026
Public float
$38.42M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
2010788
CUSIP
461874109
ISIN
US4618741098
FIGI
BBG01LFVT4P0
Share class FIGI
BBG01LFVT5J4
EIN
83-4550057

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mohammad HayatPresident & Chairman of Board, Director155,818
Damien Alan PerrimanChief Commercial Officer28,692
Tyler Paz KormanChief Scientific Officer729,123
Fouad NawazVice President- Finance9,488
Michael HeltzenChief Executive Officer14,708
Paul Hideo OpgenorthVice President, Development645,149
Edgardo Javier RayoDirector77,909
Anthony DigiandomenicoDirector3,808,476
Lon E. BellDirector–
Christopher A. MarlettDirector3,808,476
James Joseph LalondeDirector–
James Ulrich BowieDirector577,910

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 12, 2024
Offer price
$8.00
Securities offered
1,875,000
Gross proceeds
$15.00M
Exchange
Nasdaq
First trading day
Nov 13, 2024
First-day close
$8.65+8.1%
Lock-up ends (est.)
May 12, 2025

“Per Share Total Public offering price $ 8.00 $ 15,000,000.00 Underwriting discounts and commissions (8%) (1) $ 0.64 $ 1,200,000.00 Proceeds to us, before expenses $ 7.36 $ 13,800,000.00 (1) For sales of the offered shares to customers of MDB Capital, subject to deduction for expenses, MDB Capital will not be paid t”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“of December 31, 2025, eXoZymes boasts a dedicated team of approximately 32 full-time employees or equivalents.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 21, 2025Name changeName changed from Invizyne Technologies Inc to Exozymes Inc.
Nov 12, 2024IPOInitial public offering priced (424B4 prospectus)
Aug 1, 2024ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?